Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Wyeth Pharmaceuticals, a division of Wyeth has reported that the FDA has approved Pristiq for the treatment of adult patients with major depressive disorder or MDD.
Subscribe to our email newsletter
FDA approval was subject to several post-marketing commitments, including conducting and submitting data from a new long-term maintenance (relapse prevention) study, a sexual dysfunction study, pediatric studies and a study exploring lower doses. The agency also requested an additional non-clinical toxicity study. Wyeth expects to begin shipping Pristiq to wholesalers beginning in the second quarter of 2008.
Philip Ninan, vice president of Wyeth Medical Affairs, Neuroscience, said: “Pristiq is approved at a once-daily 50-mg dose that does not require titration, allowing physicians to start their patients at the recommended therapeutic dose. We are encouraged by the tolerability profile seen in clinical studies.”